Group 1 - The core viewpoint of the article is that Tigermed (stock code: 300347) has disclosed its 2025 performance forecast, indicating a significant decline in net profit excluding non-recurring gains, while net profit attributable to shareholders is expected to more than double due to non-recurring income [1][2]. Group 2 - For the year 2025, the company expects its net profit excluding non-recurring gains to be between 330 million to 490 million yuan, representing a year-on-year decline of 43% to 61% (compared to 855 million yuan in the previous year) [2]. - The decline in net profit excluding non-recurring gains is primarily attributed to issues with existing orders, including cancellations and payment pressures from clients, particularly from domestic biotech startups and some vaccine companies reliant on external financing [2]. - Increased costs due to the expansion of clinical operations, project management, and business development teams in response to industry demand recovery have also contributed to the decline in profitability [2]. - The average price of new orders has decreased due to intense industry competition in recent years, impacting the profit margins of projects executed in 2025; however, the company noted that the average price of new orders has stabilized [2]. - Despite the decline in net profit excluding non-recurring gains, the company anticipates a substantial increase in net profit attributable to shareholders, projected to be between 830 million to 1.23 billion yuan, reflecting a year-on-year growth of 105% to 204%, mainly driven by significant increases in non-recurring gains such as investment income and fair value changes [2].

Industry Overview - The pharmaceutical and biotechnology sector increased by 0.14% this week, ranking 15th among 31 primary industries in the Shenwan index, outperforming the CSI 300 index by 1.47 percentage points, which fell by 1.33% [2] - The medical services sub-sector reported a rise of 1.31%, while traditional Chinese medicine and medical commercial sectors also saw increases of 2.56% and 0.57%, respectively [2] Company Performance - Top-performing companies in the medical services sector included Meidisi (+18.0%), Tongce Medical (+8.1%), and NuoSiGe (+5.7%), while underperformers included Haoyuan Pharmaceutical (-6.2%) and Baicheng Pharmaceutical (-4.5%) [3] - CXO-related companies experienced significant pullbacks [3] Valuation Metrics - The medical services sector's price-to-earnings (PE) ratio is currently at 34.43X, with a one-year maximum of 41.13X and a minimum of 28.46X; the price-to-book (PB) ratio stands at 3.49X, with a one-year maximum of 4.00X and a minimum of 2.48X [5] - The PE ratio increased by 0.56X and the PB ratio by 0.06X compared to the previous week [5] Regulatory Developments - The National Health Commission approved a pilot program for internet-based first consultations in Beijing, focusing on pediatric specialties, which marks a significant regulatory advancement for internet healthcare in major cities [6] - This initiative is expected to enhance online medical services and provide new market opportunities for private healthcare providers [6] Investment Recommendations - The report maintains a "buy" rating for the medical services industry, suggesting a focus on high-growth areas such as ADC CDMO and weight-loss drug supply chains, as well as companies with improving profit expectations like Aier Eye Hospital and Dean Diagnostics [7] - The report emphasizes the importance of a multi-tiered payment system and the resilience of medical demand in stabilizing the industry [7]

Market Overview - The Hong Kong stock market experienced a decline, with the Hang Seng Index falling by 0.86% to 27,032.54 points, the Hang Seng Tech Index down 1.65% to 5,408.98 points, and the National Enterprises Index decreasing by 1% to 9,175.18 points [1] - Major technology stocks saw a collective drop, including Alibaba down 0.94%, Tencent down 2.28%, and Meituan down 4.5% [1] Sector Performance - Semiconductor stocks surged, with Zhaoyi Innovation rising over 20% and Wallen Technology increasing nearly 10% [1] - AI application stocks saw significant gains, particularly Zhiyuan, which spiked over 41% after the release of its new model GLM-5 [2] - Defensive sectors performed well, with Jiaxin International Resources rising over 4% and achieving a new listing high, while rare earth prices supported the performance of Jinli Permanent Magnet, which rose over 4% [3] Individual Stock Movements - Bole Electric experienced a dramatic increase of over 130%, driven by demand growth in the data center sector [5] - Tigermed Pharmaceutical's stock fell nearly 5% despite a projected net profit increase of 105% for 2025, as its core CRO business showed a decline [5] Analyst Insights - Analysts from CICC noted that the recent market pullback is due to a combination of factors including hawkish Fed expectations and concerns over AI capital expenditure returns [6] - Dongwu Securities suggested a defensive strategy due to reduced trading volume and heightened market caution [6] - Analysts from Guangfa Securities indicated that the Hong Kong market may see a temporary rise following the Lunar New Year, but warned of potential risks post-holiday [6]

泰格医药的订单情况有所改善，但市场更关注公司的订单转化收入效率及投资变现能力。由于短期利好 因素已反映在股价，相信其风险与回报已趋于平衡。 里昂发布研报称，下调泰格医药（300347）(03347)2027财年盈测7%，以反映长期投资收益的不确定因 素增加。该行续予泰格医药"跑赢大市"评级，当中将H股目标价由68.2港元下调至59.9港元，并将泰格 医药(300347.SZ)A股目标价由81.9元人民币降至72元人民币。 ...

Core Viewpoint - Credit Suisse has downgraded the earnings forecast for Tigermed (03347) for the fiscal year 2027 by 7% due to increased uncertainty regarding long-term investment returns [1] Group 1: Earnings Forecast and Ratings - The target price for Tigermed's H-shares has been reduced from HKD 68.2 to HKD 59.9 [1] - The target price for Tigermed's A-shares has been lowered from RMB 81.9 to RMB 72 [1] - The company continues to hold a "Outperform" rating despite the downgrade [1] Group 2: Market Conditions and Company Performance - Tigermed's order situation has shown improvement, but the market is more focused on the efficiency of order conversion into revenue and the company's ability to realize investment returns [1] - Short-term positive factors have already been reflected in the stock price, leading to a belief that the risk and return have become balanced [1]

消息面上，泰格医药近日公告，此预计2025年实现营业收入66.6亿-76.8亿元，同比增长1%至16%；归属 于上市公司股东的净利润为8.3亿-12.3亿元，同比增长105%至204%；归属于上市公司股东的扣除非经常 性损益后的净利润约3.3亿-4.9亿元，同比下降61%至43%。当期业绩增长主要由金融资产的投资收益和 公允价值变动贡献，而非临床CRO核心业务驱动。 里昂发布研报称，泰格医药的订单情况有所改善，但市场更关注公司的订单转化收入效率及投资变现能 力。由于短期利好因素已反映在股价，相信其风险与回报已趋于平衡。该行下调泰格医药2027财年盈测 7%，以反映长期投资收益的不确定因素增加。 泰格医药（300347）(03347)尾盘跌超5%，截至发稿，跌4.85%，报51港元，成交额1.3亿港元。 ...

消息面上，泰格医药近日公告，此预计2025年实现营业收入66.6亿-76.8亿元，同比增长1%至16%；归属 于上市公司股东的净利润为8.3亿-12.3亿元，同比增长105%至204%；归属于上市公司股东的扣除非经常 性损益后的净利润约3.3亿-4.9亿元，同比下降61%至43%。当期业绩增长主要由金融资产的投资收益和 公允价值变动贡献，而非临床CRO核心业务驱动。 里昂发布研报称，泰格医药的订单情况有所改善，但市场更关注公司的订单转化收入效率及投资变现能 力。由于短期利好因素已反映在股价，相信其风险与回报已趋于平衡。该行下调泰格医药2027财年盈测 7%，以反映长期投资收益的不确定因素增加。 智通财经APP获悉，泰格医药(03347)尾盘跌超5%，截至发稿，跌4.85%，报51港元，成交额1.3亿港 元。 ...

Group 1 - The core viewpoint of the report indicates that while the order situation for Tigermed (3347.HK) has improved, the market is more focused on the company's order conversion revenue efficiency and investment realization capability [1] - Citic Securities has lowered Tigermed's earnings forecast for the fiscal year 2027 by 7% to reflect increased uncertainty regarding long-term investment returns [1] - The target price for Tigermed's H-shares has been reduced from HKD 68.2 to HKD 59.9, and the target price for its A-shares has been decreased from RMB 81.9 to RMB 72 [1]

Market Performance - The overall performance of A-shares shows an increase in the earnings forecast rate, with a pre-announcement rate of 37% for 2025, up from 33.6% in 2024[5] - As of February 6, 2026, 54% of A-share companies have disclosed their earnings forecasts for 2025, compared to 51.2% in 2024[5] Sector Insights - The semiconductor and CXO sectors are expected to show strong performance, with the semiconductor equipment sector outperforming materials and components[2] - The non-bank financial sector has a pre-announcement rate exceeding 50%, with a median profit growth rate of 76.1%, while the real estate sector shows a median profit decline of 18.5%[11] Consumer Market - The overall retail sales growth for 2025 is projected at 3.7%, with service consumption growing at 5.5%, outperforming goods retail growth of 3.8%[13] - During the 2026 Spring Festival, domestic flight bookings increased by approximately 15% compared to the previous year, indicating a strong recovery in travel demand[19] Healthcare Sector - The pharmaceutical and biotech sector shows a mixed recovery, with 10% of companies expected to turn profitable, while 49% are projected to incur losses[21] - Notable companies like WuXi AppTec are expected to see a net profit increase of 102.65% in 2025, reaching 19.15 billion yuan[25] High-end Manufacturing - The engineering machinery sector is experiencing a recovery, with excavator sales in January 2026 reaching 18,708 units, a year-on-year increase of 49.5%[28] - The domestic sales of excavators increased by 61.4%, indicating strong internal demand recovery[30]

Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited and the Securities and Futures Commission take no responsibility for the contents of this Application Proof, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this Application Proof. Application Proof of PANACRO (Hangzhou) Pharmaceutical Technology Co., Ltd. 博納西亞 (杭 州 )醫藥科技股份有 ...